Dow Component Merck (MRK) To Go Ex-dividend Tomorrow

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

The Dow Jones Industrial Average ( ^DJI) is trading up 11 points at 15,133 as of Wednesday, Jun 12, 2013, 10:35 a.m. ET. During this time, 110.8 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 600.8 million. The NYSE advances/declines ratio sits at 1,658 issues advancing vs. 1,220 declining with 106 unchanged.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Thursday, June 13, 2013 is the ex-dividend date for Dow component Merck (NYSE: MRK). Owners of shares as of market close today will be eligible for a dividend of 43 cents per share. At a price of $48.04 as of 10:35 a.m. ET, the dividend yield is 3.5% compared to the average Dow component yield of 2.6%.

The average volume for Merck has been 18.2 million shares per day over the past 30 days. Merck has a market cap of $146.33 billion and is part of the health care sector and drugs industry. Shares are up 16.2% year to date as of Tuesday's close.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. The company has a P/E ratio of 24.7, below the average drugs industry P/E ratio of 24.9.
  • Practice your dividend trading strategies and win cash in our stock game.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
null

If you liked this article you might like

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

The 10 Stocks America's Biggest Hedge Funds Are Dumping Like Crazy

Why You Keep Cash on Hand; No Downside Conviction -- Jim Cramer's Top Thoughts